ArticleCureus2026
Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus and Recent Epstein-Barr Virus Infection: A Diagnostic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with systemic lupus erythematosus (SLE) can develop thrombocytopenia from multiple etiologies. It is important not to miss immune-mediated thrombotic thrombocytopenic purpura (TTP) as a cause of severe thrombocytopenia because untreated TTP can rapidly progress to multiorgan failure and death. The diagnosis is often challenging because autoimmune cytopenias and concurrent infections may mimic TTP. We present a case of ADAMTS13-confirmed immune-mediated TTP in a patient with SLE and recent Epstein-Barr virus (EBV) infection initially suspected to have immune thrombocytopenia. Progressive microangiopathic hemolytic anemia with worsening schistocytosis and a high PLASMIC score prompted urgent initiation of plasma exchange before ADAMTS13 confirmation. The patient was successfully treated with plasma exchange, corticosteroids, rituximab, and caplacizumab.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.